Skip to main content

Table 3 Effects of MR antagonists in peritoneal dialysis patients

From: Mineralocorticoid receptor antagonists in dialysis patients

Author

Number of patients

Administration period

Study duration

Results

Change of plasma potassium

Hausmann et al. [57]

One PD patient

Spironolactone 25 mg/day

10 months

LVEF increased.

Potassium level was below 5.1 at pretreatment and below 5.5 mEq/l after spironolactone treatment.

Taheri et al. [58]

9 PD patients with heart failure

Spironolactone 25 mg every other day

6 months

LVEF increased.

There was no significantly difference between spironolactone and placebo groups (P > 0.05). One patient in the spironolactone group developed hyperkalemia (K = 5.70 mEq/l).

Ito et al. [60]

78 PD patients

Spironolactone 25 mg/day

2 years

LV mass index and LVEF improved.

Potassium levels were significantly higher in the spironolactone group after 6 and 12 months (P < 0.05).

Two patients in the spironolactone group developed hyperkalemia (K = 6.0 mEq/l), and one patient (K = 6.1 mEq/l) in the control group.

Yongsiri et al. [59]

24 PD patients with hypokalemia

Spironolactone 25 mg/day

4 weeks

 

Potassium levels 4.23 ± 0.64 at base line and 3.90 ± 0.59 mEq/l after 4 weeks (P = 0.077). One patient in the spironolactone group developed hyperkalemia (K = 5.6 mEq/l).

Yelken et al. [72]

23 PD patients

Spironolactone 25 mg/day

6 months

Dialysate CA125 increased.

Residual GFR declined.

Potassium level 4.3 ± 0.5 at baseline and 4.4 ± 0.6 mEq/l after 6 months (P = 0.488).

Vazquez-Rangel et al. [73]

9 PD patients

Spironolactone 25 mg/day

6 months

CD20 and collagen IV levels in peritoneal biopsy specimens decreased.

Potassium levels 4.8 ± 0.4 in the spironolactone group and 4.4 ± 0.5 mEq/l in the control group (P = 0.2).

  1. CA125 cancer antigen 125, EF ejection fraction, GFR glomerular filtration rate, LV left ventricular, MR mineralocorticoid receptor, PD peritoneal dialysis